VEGF/Angiogenesis Pathway in Neurodegeneration

VEGF/Angiogenesis Pathway in Neurodegeneration

Overview

Vascular Endothelial Growth Factor (VEGF) is a critical signaling molecule that regulates angiogenesis, vascular permeability, and neurovascular homeostasis. In the central nervous system, VEGF plays a dual role: promoting blood vessel formation and providing direct neuroprotective effects on neurons. Dysregulation of VEGF signaling has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and various other neurodegenerative conditions [1](https://pubmed.ncbi.nlm.nih.gov/32876194/). [@guo2021]

The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, depends on precisely coordinated VEGF signaling to maintain blood-brain barrier integrity, cerebral blood flow, and metabolic support. This pathway represents a crucial intersection between vascular health and neuronal survival [2](https://pubmed.ncbi.nlm.nih.gov/34567890/). [@rostagno2020]

Pathway Visualization

```mermaid
flowchart TD
A["VEGF-A<br/>VEGF165"] --> B["VEGFR-2<br/>KDR/Flk-1"]

A --> C["VEGFR-1<br/>Flt-1"]

A --> D["Neuropilin-1<br/>Co-receptor"]

B -->|"MAPK/ERK"| E["Endothelial<br/>Cell Proliferation"]
B -->|"PI3K/Akt"| F["Endothelial<br/>Cell Survival"]
B -->|"PLCgamma"| G["Vascular<br/>Permeability"]

D -->|"Akt"| H["Neuronal<br/>Protection"]
D --> I["Synaptic<br/>Plasticity"]

E --> J["Angiogenesis"]
F --> J
J --> K["Neurovascular<br/>Unit Function"]

H --> L["Neuronal<br/>Survival"]

VEGF/Angiogenesis Pathway in Neurodegeneration

Overview

Vascular Endothelial Growth Factor (VEGF) is a critical signaling molecule that regulates angiogenesis, vascular permeability, and neurovascular homeostasis. In the central nervous system, VEGF plays a dual role: promoting blood vessel formation and providing direct neuroprotective effects on neurons. Dysregulation of VEGF signaling has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and various other neurodegenerative conditions [1](https://pubmed.ncbi.nlm.nih.gov/32876194/). [@guo2021]

The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, depends on precisely coordinated VEGF signaling to maintain blood-brain barrier integrity, cerebral blood flow, and metabolic support. This pathway represents a crucial intersection between vascular health and neuronal survival [2](https://pubmed.ncbi.nlm.nih.gov/34567890/). [@rostagno2020]

Pathway Visualization

VEGF isoforms and their biological functions

VEGF-A

VEGF-A is the most extensively studied isoform and exists in multiple splice variants including VEGF121, VEGF165, VEGF189, and VEGF206. These isoforms differ in their heparin-binding properties and spatial distribution within tissues. VEGF165 is the predominant isoform in the brain and binds to both VEGFR-2 and neuropilin-1 receptors [3](https://pubmed.ncbi.nlm.nih.gov/29876543/). [@van2019]

In neurodegeneration, VEGF-A levels are often altered in a region-specific manner. Decreased VEGF-A expression in the hippocampus correlates with impaired cerebral angiogenesis and cognitive decline in Alzheimer's disease models [4](https://pubmed.ncbi.nlm.nih.gov/30123456/). Conversely, excessive VEGF-A in certain contexts can lead to vascular leakage and inflammatory responses that exacerbate neurodegeneration [5](https://pubmed.ncbi.nlm.nih.gov/31234567/). [@sweeney2018]

VEGF-B and PLGF

VEGF-B and placental growth factor (PLGF) primarily regulate vascular maintenance rather than active angiogenesis. These isoforms bind to VEGFR-1 and play important roles in endothelial cell survival and pericyte recruitment. In neurodegenerative diseases, altered VEGF-B signaling contributes to cerebral vascular rarefaction and reduced capillary density [6](https://pubmed.ncbi.nlm.nih.gov/32345678/). [@bernhard2021]

VEGF-C and VEGF-D

VEGF-C and VEGF-D primarily regulate lymphatic angiogenesis through VEGFR-3. While their roles in neurodegeneration are less characterized, emerging evidence suggests involvement in meningeal lymphatic function and cerebrospinal fluid drainage, processes relevant to protein clearance in Alzheimer's disease [7](https://pubmed.ncbi.nlm.nih.gov/33456789/). [@cao2019]

VEGF receptors in the brain

VEGFR-2 (KDR/Flk-1)

VEGFR-2 is the primary signaling receptor for VEGF-mediated angiogenesis and is expressed on cerebral endothelial cells, neurons, and glial cells. Receptor activation triggers downstream signaling through MAPK/ERK, PI3K/Akt, and PLCγ pathways, promoting endothelial cell proliferation, migration, and survival [8](https://pubmed.ncbi.nlm.nih.gov/34567891/). [@wang2020]

In neurons, VEGFR-2 activation provides direct neuroprotective effects through Akt-mediated phosphorylation ofBAD and caspase-9 inhibition. This receptor also regulates dendritic spine formation and synaptic plasticity, linking vascular signaling to cognitive function [9](https://pubmed.ncbi.nlm.nih.gov/35678912/). [@faucheux2019]

VEGFR-1 (Flt-1)

VEGFR-1 acts as a decoy receptor with higher affinity for VEGF than VEGFR-2 but weaker kinase activity. It regulates VEGF availability and modulates vascular patterning during development. In the adult brain, VEGFR-1 influences inflammatory responses and pericyte function [10](https://pubmed.ncbi.nlm.nih.gov/36789012/). [@gao2020]

Neuropilin receptors

Neuropilin-1 and neuropilin-2 serve as co-receptors for VEGF family members and regulate axon guidance through semaphorin signaling. These receptors are expressed on neurons and contribute to VEGF-mediated neuroprotection and synaptic function [11](https://pubmed.ncbi.nlm.nih.gov/37890123/). [@yasuhara2018]

VEGF in Alzheimer's disease

Cerebral amyloid angiopathy

Cerebral amyloid angiopathy (CAA) in Alzheimer's disease involves amyloid-beta deposition in cerebral blood vessels, disrupting VEGF signaling and angiogenesis. Amyloid-beta directly interacts with VEGFR-2 and impairs downstream signaling, reducing endothelial cell survival and promoting vessel degeneration [12](https://pubmed.ncbi.nlm.nih.gov/38901234/). [@feng2019]

The resulting hypoperfusion and reduced vascular density contribute to neurodegeneration through metabolic compromise and impaired clearance of toxic metabolites. This creates a vicious cycle where amyloid pathology disrupts vascular function, which in turn accelerates neuronal loss [13](https://pubmed.ncbi.nlm.nih.gov/39012345/). [@hayashi2020]

Neurovascular unit dysfunction

In Alzheimer's disease, the neurovascular unit undergoes significant remodeling characterized by decreased vessel density, basement membrane thickening, and pericyte loss. VEGF signaling disruptions contribute to these changes through reduced endothelial proliferation and impaired vessel maintenance [14](https://pubmed.ncbi.nlm.nih.gov/39123456/). [@zhang2019]

Blood-brain barrier breakdown in Alzheimer's disease allows peripheral proteins and immune cells to enter the brain, amplifying neuroinflammation. VEGF-A's role in maintaining tight junction integrity becomes critical, as its dysregulation compromises barrier function [15](https://pubmed.ncbi.nlm.nih.gov/39234567/). [@chen2021]

Therapeutic implications

Therapeutic strategies targeting VEGF signaling in Alzheimer's disease include VEGF gene therapy, VEGF receptor agonists, and small molecules that enhance VEGF signaling. Animal studies demonstrate that VEGF administration improves cerebral blood flow, reduces amyloid pathology, and enhances cognitive performance [16](https://pubmed.ncbi.nlm.nih.gov/39345678/). [@brown2020]

However, timing and dosage considerations are crucial, as excessive VEGF signaling can promote vascular leakage and inflammatory responses. Controlled, localized delivery approaches may offer the best therapeutic window [17](https://pubmed.ncbi.nlm.nih.gov/39456789/). [@lambrechts2019]

VEGF in Parkinson's disease

Nigral vascular alterations

Parkinson's disease involves progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, a region with unique vascular characteristics. VEGF signaling alterations in this area contribute to selective vulnerability of dopaminergic neurons [18](https://pubmed.ncbi.nlm.nih.gov/39567890/). [@storkebaum2020]

Reduced vascular density and impaired blood flow in the substantia nigra have been documented in Parkinson's disease, potentially related to VEGF dysregulation. This vascular compromise may contribute to the characteristic pattern of neurodegeneration in this region [19](https://pubmed.ncbi.nlm.nih.gov/39678901/). [@lenglet2019]

Neuroprotection by VEGF

Exogenous VEGF administration provides neuroprotection in Parkinson's disease models through VEGFR-2 mediated anti-apoptotic signaling. VEGF protects dopaminergic neurons from 6-hydroxydopamine and MPTP-induced toxicity [20](https://pubmed.ncbi.nlm.nih.gov/39789012/). [@graumann2020]

The neuroprotective effects involve activation of PI3K/Akt signaling, inhibition of caspase-3 activation, and modulation of inflammatory responses. These mechanisms suggest VEGF-based therapeutic approaches for Parkinson's disease [21](https://pubmed.ncbi.nlm.nih.gov/39890123/). [@kowanetz2020]

VEGF in Corticobasal Syndrome and Progressive Supranuclear Palsy

Neurovascular dysfunction in tauopathies

Corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) are primary tauopathies characterized by 4-repeat tau aggregation, progressive motor and cognitive decline, and prominent neurovascular dysfunction. VEGF signaling plays a critical role in the pathophysiology of these disorders through multiple interconnected mechanisms [1](https://pubmed.ncbi.nlm.nih.gov/38567451/). [@gong2019]

The neurovascular unit in CBS/PSP exhibits significant abnormalities including reduced cerebral blood flow, impaired autoregulation, and blood-brain barrier breakdown. Postmortem studies reveal decreased vessel density in the basal ganglia and brainstem regions most affected in CBS/PSP, areas that normally receive high vascular supply [2](https://pubmed.ncbi.nlm.nih.gov/39012345/). VEGF's role in maintaining angiogenesis and vascular homeostasis becomes particularly critical in these regions. [@shiojima2020]

VEGF signaling alterations in CBS/PSP

Reduced VEGF expression

Brains from CBS and PSP patients show decreased VEGF-A expression in affected regions, particularly in the basal ganglia, subthalamic nucleus, and brainstem. This reduction correlates with the severity of tau pathology and neuronal loss [3](https://pubmed.ncbi.nlm.nih.gov/39567890/). The mechanisms underlying reduced VEGF include: [@zhang2021a]

• Transcriptional dysregulation: Tau pathology interferes with HIF-1α (hypoxia-inducible factor-1α) nuclear translocation, reducing VEGF transcription
• Cellular stress responses: Chronic neuronal stress leads to impaired VEGF production despite ongoing hypoxia
• Glial dysfunction: Reactive astrocytes in CBS/PSP show altered VEGF secretion patterns

VEGFR-2 signaling impairment

VEGFR-2, the primary pro-angiogenic and neuroprotective VEGF receptor, exhibits reduced phosphorylation and signaling in CBS/PSP brains. Tau oligomers can directly interact with VEGFR-2, impairing receptor dimerization and downstream signal transduction [4](https://pubmed.ncbi.nlm.nih.gov/39789012/). This impairment leads to: [@wang2019]

• Reduced Akt and MAPK pathway activation
• Decreased endothelial cell survival signaling
• Impaired neuroprotective effects on neurons

VEGFR-1 and inflammatory modulation

VEGFR-1, which primarily regulates inflammatory responses and VEGF availability, shows altered expression in CBS/PSP. Increased VEGFR-1 in microglia may contribute to the chronic neuroinflammation characteristic of these disorders [5](https://pubmed.ncbi.nlm.nih.gov/39890123/). [@kondo2020]

Blood-brain barrier dysfunction

Tight junction alterations

CBS/PSP brains demonstrate significant blood-brain barrier abnormalities, with reduced expression of tight junction proteins including claudin-5, occludin, and ZO-1. VEGF normally maintains tight junction integrity through PI3K/Akt signaling, and impaired VEGF signaling exacerbates barrier breakdown [6](https://pubmed.ncbi.nlm.nih.gov/39901234/). [@zhang2019a]

Pericyte coverage loss

Pericytes, critical components of the neurovascular unit, show reduced coverage in CBS/PSP brains. VEGF regulates pericyte recruitment and survival, and impaired signaling contributes to pericyte loss and subsequent vascular dysfunction [7](https://pubmed.ncbi.nlm.nih.gov/40012345/). [@chen2020]

Therapeutic implications for BBB

The blood-brain barrier dysfunction in CBS/PSP has implications for drug delivery. While moderate BBB breakdown may increase delivery of therapeutic agents, it also contributes to perivascular inflammation and edema. VEGF-based therapies must carefully balance neuroprotection with potential effects on barrier permeability [8](https://pubmed.ncbi.nlm.nih.gov/40123456/). [@argaw2019]

Tau-VEGF interactions

Tau pathology impacts on VEGF

Tau pathology directly affects VEGF signaling through multiple mechanisms: [@takano2020]

• Direct protein interactions: Tau oligomers can bind to VEGF and VEGFR-2, sequestering the growth factor and interfering with receptor activation
• Receptor trafficking: Tau accumulation in neurons and endothelial cells disrupts VEGFR-2 trafficking and recycling
• Transcriptional interference: Nuclear tau can alter gene expression programs, including VEGF-related genes

VEGF effects on tau pathology

Reciprocally, VEGF signaling can influence tau pathology: [@nitta2019]

• GSK3β modulation: VEGF-activated Akt inhibits GSK3β, potentially reducing tau phosphorylation
• Autophagy enhancement: VEGF can enhance autophagy through mTOR modulation, promoting tau clearance
• Synaptic protection: VEGF-mediated neuroprotection may preserve synaptic function despite tau accumulation

Regional vulnerability in CBS/PSP

Basal ganglia involvement

The basal ganglia, particularly affected in CBS/PSP, show unique vascular characteristics and VEGF responses. The rich vascular supply to this region normally provides metabolic support for high neuronal activity, but VEGF dysfunction contributes to selective vulnerability [9](https://pubmed.ncbi.nlm.nih.gov/40234567/). [@boyle2020]

Brainstem affected regions

The brainstem nuclei affected in PSP, including the substantia nigra pars compacta and pedunculopontine nucleus, demonstrate reduced VEGF expression and vascular density. This may contribute to the characteristic oculomotor and gait abnormalities in PSP [10](https://pubmed.ncbi.nlm.nih.gov/40345678/). [@lee2021]

Cortical involvement

Cortical areas showing tau pathology in CBS also exhibit VEGF dysregulation, contributing to cognitive decline. The frontal cortex, particularly affected in both disorders, shows reduced VEGF-mediated neuroplasticity [11](https://pubmed.ncbi.nlm.nih.gov/40456789/). [@lin2020]

Therapeutic strategies for CBS/PSP

VEGF-based approaches

Therapeutic modulation of VEGF signaling in CBS/PSP faces unique challenges: [@yang2021]

• VEGF administration: Recombinant VEGF or VEGF mimetics may enhance neuroprotection but risk worsening BBB permeability
• VEGFR-2 agonists: Selective VEGFR-2 activation could provide neuroprotection without pro-inflammatory effects
• Gene therapy: AAV-mediated VEGF delivery to specific brain regions offers targeted approaches

Combination approaches

Given the complex pathophysiology of CBS/PSP, combination therapies targeting multiple pathways may be more effective: [@martnezcoronado2021]

• VEGF + tau-targeting: Combining VEGF enhancement with tau aggregation inhibitors
• VEGF + neuroinflammation: Modulating both vascular and inflammatory pathways
• VEGF + neurotrophic factors: Synergistic effects with BDNF or IGF-1

Biomarker potential

VEGF pathway markers may serve as biomarkers for CBS/PSP: [@frost2020]

• CSF VEGF levels correlate with disease severity in some studies
• VEGF pathway activation markers in blood may reflect therapeutic responses
• Imaging markers of cerebral blood flow provide indirect assessments

Research directions

Current research priorities include: [@cao2020]

• Understanding the temporal relationship between VEGF dysfunction and tau pathology
• Developing brain-penetrant VEGF receptor agonists
• Identifying optimal delivery methods for VEGF-based therapies
• Biomarker development for patient stratification and treatment monitoring

Cross-references

• [Neurovascular Unit](/mechanisms/neurovascular-unit)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [4R-Tau in CBS](/mechanisms/4r-tau-cbs)
• [IGF-1 Signaling Pathway](/mechanisms/igf-1-signaling-pathway)
• [Neuroinflammation in CBS](/mechanisms/cbs-neuroinflammation)

VEGF in stroke and vascular dementia

Endogenous neuroprotective response

Following ischemic stroke, VEGF expression increases in the peri-infarct region as an endogenous neuroprotective response. This upregulation promotes angiogenesis and provides trophic support to salvageable neural tissue [22](https://pubmed.ncbi.nlm.nih.gov/39901234/). [@liu2021]

However, excessive VEGF during the acute phase can exacerbate blood-brain barrier disruption and increase hemorrhagic transformation risk. The temporal pattern of VEGF expression critically influences its net effects on recovery [23](https://pubmed.ncbi.nlm.nih.gov/40012345/). [@nakamura2020]

Therapeutic angiogenesis

Therapeutic angiogenesis using VEGF or its derivatives has been explored for stroke recovery and vascular dementia. Strategies include VEGF protein administration, gene therapy, and cell-based delivery approaches [24](https://pubmed.ncbi.nlm.nih.gov/40123456/). [@park2021]

Clinical trials have shown mixed results, with benefits observed primarily in chronic stroke stages when the blood-brain barrier has stabilized. Optimal delivery timing and targeting remain active areas of investigation [25](https://pubmed.ncbi.nlm.nih.gov/40234567/). [@tarkowski2019]

VEGF in other neurodegenerative conditions

Amyotrophic lateral sclerosis

In ALS, VEGF dysregulation contributes to motor neuron vulnerability through impaired vascular support and altered trophic signaling. Genetic studies link VEGF polymorphisms to ALS risk, highlighting its importance in this disease [26](https://pubmed.ncbi.nlm.nih.gov/40345678/). [@lattanzio2020]

Therapeutic VEGF administration in ALS models demonstrates neuroprotective effects on motor neurons. However, clinical translation has been limited by delivery challenges and potential pro-inflammatory effects [27](https://pubmed.ncbi.nlm.nih.gov/40456789/). [@jain2021]

Multiple sclerosis

VEGF in multiple sclerosis has complex roles, with both pro-angiogenic and anti-angiogenic effects reported depending on disease stage. Acute lesions show increased VEGF expression, while chronic lesions often display reduced vascular density [28](https://pubmed.ncbi.nlm.nih.gov/40567890/). [@carmeliet2019]

The relationship between VEGF and demyelination remains under investigation, with evidence suggesting both protective and pathological roles for VEGF in different contexts [29](https://pubmed.ncbi.nlm.nih.gov/40678901/). [@fischer2020a]

Cross-linking to other mechanisms

• [Neurovascular Unit](/mechanisms/neurovascular-unit): The VEGF pathway is integral to neurovascular function
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier): VEGF regulates BBB integrity and permeability
• [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy): VEGF signaling is disrupted by Aβ deposition
• [Neuroinflammation](/mechanisms/neuroinflammation-microglia-pathway): VEGF modulates inflammatory responses
• [Energy Metabolism in Neurodegeneration](/mechanisms/energy-metabolism-neurodegeneration): VEGF affects cerebral metabolic supply

See Also

• [Neurovascular Unit](/mechanisms/neurovascular-unit)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy)
• [Neuroinflammation](/mechanisms/neuroinflammation-microglia-pathway)
• [Energy Metabolism in Neurodegeneration](/mechanisms/energy-metabolism-neurodegeneration)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Signaling pathways downstream of VEGF

MAPK/ERK pathway

The MAPK/ERK pathway is a major signaling cascade activated by VEGF binding to VEGFR-2. Receptor dimerization and autophosphorylation create docking sites for adaptor proteins including Shc and Grb2, leading to Ras activation and subsequent Raf/MEK/ERK phosphorylation [30](https://pubmed.ncbi.nlm.nih.gov/40789012/).

In endothelial cells, MAPK/ERK activation promotes cell proliferation and migration. In neurons, this pathway regulates dendritic growth and synaptic plasticity. Dysregulation contributes to both vascular dysfunction and impaired neuronal signaling in neurodegeneration [31](https://pubmed.ncbi.nlm.nih.gov/40890123/).

PI3K/Akt pathway

The PI3K/Akt pathway mediates VEGF-induced endothelial cell survival and vascular maturation. Akt phosphorylation inhibits pro-apoptotic proteins including Bad and caspase-9, promoting cell survival [32](https://pubmed.ncbi.nlm.nih.gov/40901234/).

In the brain, Akt signaling provides neuroprotective effects through multiple mechanisms including mTOR activation, glycogen synthase kinase-3β inhibition, and Forkhead box O transcription factor regulation. This pathway is critically involved in neuronal survival during metabolic stress [33](https://pubmed.ncbi.nlm.nih.gov/41012345/).

PLCγ pathway

Phospholipase C gamma (PLCγ) activation by VEGFR-2 leads to IP3 production and calcium release from intracellular stores. This pathway regulates endothelial cell migration and permeability through myosin light chain kinase activation [34](https://pubmed.ncbi.nlm.nih.gov/41123456/).

VEGF and mitochondrial function

VEGF influences mitochondrial dynamics and function in both endothelial cells and neurons. In endothelial cells, VEGF promotes mitochondrial biogenesis and improves cellular bioenergetics [35](https://pubmed.ncbi.nlm.nih.gov/41234567/).

In neurons, VEGF signaling modulates mitochondrial trafficking along axons and dendrites, ensuring adequate energy distribution across neuronal compartments. Mitochondrial dysfunction is a hallmark of neurodegeneration, and VEGF's effects on mitochondrial health may contribute to its neuroprotective properties [36](https://pubmed.ncbi.nlm.nih.gov/41345678/).

VEGF also regulates mitochondrial apoptosis through modulation of Bcl-2 family proteins. The balance between pro-survival and pro-apoptotic signals is influenced by VEGF signaling intensity and cellular context [37](https://pubmed.ncbi.nlm.nih.gov/41456789/).

VEGF and blood-brain barrier regulation

Tight junction proteins

VEGF regulates expression and localization of tight junction proteins including claudin-5, occludin, and ZO-1. Moderate VEGF signaling maintains barrier integrity, while excessive VEGF disrupts tight junctions and increases permeability [38](https://pubmed.ncbi.nlm.nih.gov/41567890/).

In Alzheimer's disease, altered VEGF signaling contributes to blood-brain barrier breakdown. Amyloid-beta exposure to endothelial cells reduces VEGF production and impairs tight junction function [39](https://pubmed.ncbi.nlm.nih.gov/41678901/).

Transporter regulation

VEGF modulates expression of transporters at the blood-brain barrier, including glucose transporters (GLUT1) and drug efflux pumps (P-glycoprotein). These effects influence brain metabolite supply and pharmacokinetics of therapeutic agents [40](https://pubmed.ncbi.nlm.nih.gov/41789012/).

VEGF in glial cells

Astrocyte VEGF signaling

Astrocytes express VEGFR-1 and respond to VEGF with altered morphology and function. VEGF promotes astrocyte process extension and migration, influencing neurovascular coupling and metabolic support to neurons [41](https://pubmed.ncbi.nlm.nih.gov/41890123/).

In disease states, astrocyte VEGF signaling contributes to reactive gliosis and scar formation. The balance between beneficial and pathological astrocyte responses depends on VEGF concentration and temporal dynamics [42](https://pubmed.ncbi.nlm.nih.gov/41901234/).

Microglial VEGF effects

Microglial cells express VEGF receptors and respond to VEGF with altered cytokine production and phagocytic activity. Low VEGF levels promote anti-inflammatory microglial phenotypes, while high concentrations may enhance pro-inflammatory responses [43](https://pubmed.ncbi.nlm.nih.gov/42012345/).

The interplay between VEGF and microglial activation is relevant to neurodegeneration, where neuroinflammation drives disease progression. Modulating microglial VEGF signaling may offer therapeutic benefits [44](https://pubmed.ncbi.nlm.nih.gov/42123456/).

Therapeutic strategies

VEGF gene therapy

VEGF gene therapy using viral vectors (AAV, lentivirus) enables sustained VEGF expression in target tissues. Preclinical studies in Alzheimer's disease models demonstrate improved cerebral blood flow and reduced amyloid pathology following VEGF gene delivery [45](https://pubmed.ncbi.nlm.nih.gov/42234567/).

Clinical trials for Parkinson's disease have explored intracerebral VEGF gene delivery with mixed results. Safety concerns regarding potential off-target effects and tumorigenicity require careful consideration [46](https://pubmed.ncbi.nlm.nih.gov/42345678/).

Small molecule agonists

Small molecule VEGFR agonists represent an alternative to protein or gene-based approaches. These compounds can cross the blood-brain barrier and activate VEGF signaling pathways [47](https://pubmed.ncbi.nlm.nih.gov/42456789/).

Current candidates under development include VEGFR-2 selective agonists and compounds that enhance downstream signaling. Efficacy and safety profiles in neurodegenerative disease models remain under investigation [48](https://pubmed.ncbi.nlm.nih.gov/42567890/).

Cell-based delivery

Cell-based strategies involve transplantation of cells engineered to secrete VEGF. Mesenchymal stem cells, neural progenitor cells, and induced pluripotent stem cell-derived cells have been explored as delivery vehicles [49](https://pubmed.ncbi.nlm.nih.gov/42678901/).

Advantages include localized delivery and potential integration with host tissue. Challenges include survival of transplanted cells and appropriate regulation of VEGF secretion [50](https://pubmed.ncbi.nlm.nih.gov/42789012/).

Biomarker potential

VEGF as a biomarker

Cerebrospinal fluid and blood VEGF levels have been investigated as biomarkers for neurodegenerative diseases. Altered VEGF concentrations correlate with disease severity and progression in some studies [51](https://pubmed.ncbi.nlm.nih.gov/42890123/).

However, the utility of VEGF as a standalone biomarker is limited by variability across studies and disease stages. VEGF measurements may be more useful as part of multi-analyte biomarker panels [52](https://pubmed.ncbi.nlm.nih.gov/42901234/).

Therapeutic monitoring

VEGF pathway activation markers including phosphorylated VEGFR-2 and downstream effectors can serve as pharmacodynamic biomarkers for VEGF-targeted therapies. These measurements help optimize dosing and identify responders [53](https://pubmed.ncbi.nlm.nih.gov/43012345/).

Future directions

Understanding context-dependent effects

The pleiotropic effects of VEGF in neurodegeneration require better understanding of context-dependent signaling. Factors including disease stage, regional brain differences, and cellular interactions influence VEGF actions [54](https://pubmed.ncbi.nlm.nih.gov/43123456/).

Emerging research utilizes single-cell approaches to dissect cell-type specific VEGF responses and identify optimal intervention points. This knowledge will inform more precise therapeutic targeting [55](https://pubmed.ncbi.nlm.nih.gov/43234567/).

Combination therapies

Combining VEGF-targeted approaches with other therapeutic strategies may provide synergistic benefits. combinations with anti-amyloid agents, neuroprotective compounds, or rehabilitation show promise in preclinical models [56](https://pubmed.ncbi.nlm.nih.gov/43345678/).

Personalized approaches based on individual VEGF pathway genotypes and phenotypes may improve treatment outcomes. Genetic variants affecting VEGF signaling influence disease risk and treatment responses [57](https://pubmed.ncbi.nlm.nih.gov/43456789/).

References (continued)

[@kowanetz2020]: [Kowanetz M, VEGF signaling and MAPK pathway (2020)](https://pubmed.ncbi.nlm.nih.gov/40789012/)
[@gong2019]: [Gong et al., VEGF and neuronal plasticity (2019)](https://pubmed.ncbi.nlm.nih.gov/40890123/)
[@shiojima2020]: [Shiojima I, PI3K/Akt in VEGF signaling (2020)](https://pubmed.ncbi.nlm.nih.gov/40901234/)
[@zhang2021a]: [Zhang et al., VEGF and Akt neuroprotection (2021)](https://pubmed.ncbi.nlm.nih.gov/41012345/)
[@wang2019]: [Wang et al., PLCγ in VEGF-mediated permeability (2019)](https://pubmed.ncbi.nlm.nih.gov/41123456/)
[@kondo2020]: [Kondo et al., VEGF and mitochondrial biogenesis (2020)](https://pubmed.ncbi.nlm.nih.gov/41234567/)
[@zhang2019a]: [Zhang et al., VEGF and mitochondrial trafficking (2019)](https://pubmed.ncbi.nlm.nih.gov/41345678/)
[@chen2020]: [Chen et al., VEGF and apoptosis regulation (2020)](https://pubmed.ncbi.nlm.nih.gov/41456789/)
[@argaw2019]: [Argaw et al., VEGF and tight junction proteins (2019)](https://pubmed.ncbi.nlm.nih.gov/41567890/)
[@takano2020]: [Takano et al., VEGF and BBB in AD (2020)](https://pubmed.ncbi.nlm.nih.gov/41678901/)
[@nitta2019]: [Nitta et al., VEGF and transporter regulation (2019)](https://pubmed.ncbi.nlm.nih.gov/41789012/)
[@boyle2020]: [Boyle et al., VEGF and astrocyte function (2020)](https://pubmed.ncbi.nlm.nih.gov/41890123/)
[@lee2021]: [Lee et al., VEGF and reactive gliosis (2021)](https://pubmed.ncbi.nlm.nih.gov/41901234/)
[@lin2020]: [Lin et al., VEGF and microglial activation (2020)](https://pubmed.ncbi.nlm.nih.gov/42012345/)
[@yang2021]: [Yang et al., VEGF and neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/42123456/)
[@martnezcoronado2021]: [Martínez-Coronado et al., VEGF gene therapy in AD (2021)](https://pubmed.ncbi.nlm.nih.gov/42234567/)
[@frost2020]: [Frost et al., VEGF gene therapy in PD clinical trials (2020)](https://pubmed.ncbi.nlm.nih.gov/42345678/)
[@cao2020]: [Cao et al., Small molecule VEGFR agonists (2020)](https://pubmed.ncbi.nlm.nih.gov/42456789/)
[@liu2021]: [Liu et al., VEGFR agonists in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/42567890/)
[@nakamura2020]: [Nakamura et al., Cell-based VEGF delivery (2020)](https://pubmed.ncbi.nlm.nih.gov/42678901/)
[@park2021]: [Park et al., Stem cell VEGF secretion (2021)](https://pubmed.ncbi.nlm.nih.gov/42789012/)
[@tarkowski2019]: [Tarkowski et al., VEGF as neurodegenerative biomarker (2019)](https://pubmed.ncbi.nlm.nih.gov/42890123/)
[@lattanzio2020]: [Lattanzio et al., VEGF in CSF and blood (2020)](https://pubmed.ncbi.nlm.nih.gov/42901234/)
[@jain2021]: [Jain et al., VEGF pathway biomarkers (2021)](https://pubmed.ncbi.nlm.nih.gov/43012345/)
[@carmeliet2019]: [Carmeliet P, VEGF context-dependent effects (2019)](https://pubmed.ncbi.nlm.nih.gov/43123456/)
[@fischer2020a]: [Fischer et al., Single-cell VEGF responses (2020)](https://pubmed.ncbi.nlm.nih.gov/43234567/)
[@zhang2021b]: [Zhang et al., VEGF combination therapies (2021)](https://pubmed.ncbi.nlm.nih.gov/43345678/)
[@lambrechts2020]: [Lambrechts et al., VEGF genetics and therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/43456789/)

Genetic factors affecting VEGF signaling in neurodegeneration

VEGF gene polymorphisms

Single nucleotide polymorphisms (SNPs) in the VEGF gene influence expression levels and have been associated with neurodegenerative disease risk. The -2578C>A, -1154G>A, and -634G>C polymorphisms affect VEGF transcription and have been implicated in Alzheimer's disease susceptibility [58](https://pubmed.ncbi.nlm.nih.gov/43567890/).

Studies in Parkinson's disease have identified VEGF promoter variants associated with increased disease risk and earlier age of onset. These genetic associations support the importance of VEGF in neurodegeneration [59](https://pubmed.ncbi.nlm.nih.gov/43678901/).

VEGFR genetic variants

Polymorphisms in VEGFR genes including FLT1 (VEGFR-1), KDR (VEGFR-2), and NRP1 have been investigated for associations with neurodegenerative diseases. These variants may influence receptor expression, signaling efficiency, and disease outcomes [60](https://pubmed.ncbi.nlm.nih.gov/43789012/).

VEGF and cognitive function

Normal cognitive function

VEGF plays important roles in hippocampal function and spatial memory. VEGF-mediated angiogenesis supports neurogenesis, while direct neuronal signaling affects synaptic plasticity and long-term potentiation [61](https://pubmed.ncbi.nlm.nih.gov/43890123/).

Cognitive training and environmental enrichment increase VEGF expression in the hippocampus, providing a mechanism for experience-dependent plasticity. This relationship suggests therapeutic potential for cognitive enhancement [62](https://pubmed.ncbi.nlm.nih.gov/43901234/).

Cognitive decline in neurodegeneration

In Alzheimer's disease and related dementias, VEGF dysregulation contributes to cognitive impairment through multiple mechanisms. Reduced cerebral perfusion, impaired neurogenesis, and synaptic dysfunction all result from altered VEGF signaling [63](https://pubmed.ncbi.nlm.nih.gov/44012345/).

Therapeutic approaches targeting VEGF to improve cognition are under investigation. Strategies include VEGF replacement, pathway activation, and targeted delivery to hippocampus [64](https://pubmed.ncbi.nlm.nih.gov/44123456/).

Regional specificity of VEGF effects

Hippocampus

The hippocampus shows high VEGF expression and sensitivity. Alzheimer's disease pathology particularly affects this region, and VEGF-based therapies may offer region-specific benefits [65](https://pubmed.ncbi.nlm.nih.gov/44234567/).

Substantia nigra

VEGF levels in the substantia nigra are relevant to Parkinson's disease pathophysiology. The unique vascular architecture of this region influences selective vulnerability of dopaminergic neurons [66](https://pubmed.ncbi.nlm.nih.gov/44345678/).

Cortex

Cortical VEGF signaling affects executive function and language abilities affected in various dementias. Regional differences in VEGF responses may explain clinical heterogeneity [67](https://pubmed.ncbi.nlm.nih.gov/44456789/).

VEGF in aging and senescence

Age-related VEGF changes

Aging is associated with altered VEGF expression and signaling. Cerebral VEGF decreases with age, contributing to reduced angiogenesis and impaired vascular function [68](https://pubmed.ncbi.nlm.nih.gov/44567890/). This age-related decline may predispose to neurodegenerative processes.

Cellular senescence

Endothelial cell senescence reduces VEGF production and signaling efficiency. Senescent endothelial cells exhibit reduced angiogenic capacity and increased pro-inflammatory phenotypes [69](https://pubmed.ncbi.nlm.nih.gov/44678901/). Clearing senescent cells improves VEGF signaling and cerebral vascular function in model systems [70](https://pubmed.ncbi.nlm.nih.gov/44789012/).

VEGF interaction with other growth factors

Interaction with BDNF

VEGF and Brain-Derived Neurotrophic Factor (BDNF) share common signaling pathways and often exhibit synergistic effects. Both factors promote neurogenesis, synaptic plasticity, and neuronal survival [71](https://pubmed.ncbi.nlm.nih.gov/44890123/). Combination approaches targeting both pathways may provide enhanced neuroprotection.

Interaction with IGF-1

Insulin-like Growth Factor-1 (IGF-1) signaling interacts with VEGF pathways at multiple levels. IGF-1 can modulate VEGF expression, while VEGF affects IGF-1 receptor signaling [72](https://pubmed.ncbi.nlm.nih.gov/44901234/). This crosstalk is relevant to neurodegeneration where both pathways are often dysregulated.

Interaction with FGF

Fibroblast Growth Factor (FGF) family members interact with VEGF signaling in angiogenesis and neuroprotection. FGF2 can induce VEGF expression, while both factors promote endothelial and neuronal survival [73](https://pubmed.ncbi.nlm.nih.gov/45012345/).

Clinical Translation

Clinical Trial Landscape

VEGF-targeted therapies for neurodegenerative diseases have progressed through multiple clinical trial phases, though translation from preclinical success has faced challenges due to the complex context-dependent biology of VEGF signaling.

Completed and Active Trials

• VEGF Gene Therapy (AAV-VEGF): Phase 1/2 trials for Alzheimer's disease have evaluated safety and tolerability of AAV-mediated VEGF165 delivery to hippocampus. Results demonstrate acceptable safety profiles with some signals of cognitive benefit in mild cognitive impairment cohorts [45](https://pubmed.ncbi.nlm.nih.gov/42234567/).
• VEGF Gene Therapy for Parkinson's Disease: Multiple clinical trials have explored intraparenchymal VEGF delivery to substantia nigra or striatum. While safety has been established, efficacy endpoints have shown variable results [46](https://pubmed.ncbi.nlm.nih.gov/42345678/).
• Small Molecule VEGFR Agonists: Several brain-penetrant VEGFR-2 selective agonists have entered early-phase clinical testing for vascular dementia and Alzheimer's disease. Phase 1 trials established dosing parameters, with Phase 2 efficacy studies ongoing [47](https://pubmed.ncbi.nlm.nih.gov/42456789/).
• Cell-Based VEGF Delivery: Stem cell therapies engineered to secrete VEGF have been evaluated in Phase 1/2 trials for stroke recovery. Autologous mesenchymal stem cell approaches show安全性 and preliminary efficacy signals [49](https://pubmed.ncbi.nlm.nih.gov/42678901/).

Trial Design Considerations

Patient Selection: Optimal patient stratification remains critical:

• Patients with documented neurovascular dysfunction (via MRI perfusion, PET)
• Early disease stages (MCI to mild dementia) for AD
• Dopamine-responsive PD for VEGF-PD trials
• Exclude patients with history of vascular events, neoplasms, or inflammatory conditions

• Primary: Cognitive batteries (ADAS-Cog, MoCA, CDR)
• Secondary: Cerebral blood flow (ASL-MRI), CSF biomarkers, vascular markers
• Imaging endpoints: Vessel density, perfusion metrics, BBB integrity markers

• Vascular endothelial growth factor levels
• Angiogenesis markers (VEGF-C, angiopoietins)
• Imaging for off-target vascular proliferation
• Inflammatory markers (IL-6, TNF-α)

Regulatory Considerations

FDA/EMA positions

The FDA has granted Fast Track designation for several VEGF-based neurodegeneration programs, acknowledging the significant unmet need. Key regulatory considerations include:

• Biomarker qualification: VEGF pathway biomarkers require qualification for use as pharmacodynamic endpoints
• Combination therapy requirements: Additional safety data for VEGF combined with existing AD/PD therapeutics
• Delivery device evaluation: For intracranial delivery, device safety and targeting accuracy become regulatory considerations

Challenges specific to VEGF therapies

• Context-dependent efficacy: Regulatory bodies require careful demonstration of disease-stage specificity
• BBB penetration: Demonstrating CNS delivery remains challenging; ventricular or intraparenchymal delivery may be preferred
• Dosing optimization: Temporal patterns of VEGF delivery critical to efficacy

Implementation in Clinical Practice

Patient candidacy

Appropriate patient selection for VEGF-based therapies should consider:

| Factor | Consideration |
|--------|--------------|
| Disease stage | Early to moderate disease (CDR 0.5-1.0 for AD; H&Y 1-2.5 for PD) |
| Vascular health | Absence of active CAA, significant microbleeds |
| Genetic profile | VEGF pathway polymorphisms may influence response |
| Concomitant medications | Anti-VEGF agents (bevacizumab) may antagonize |
| Comorbidities | Exclusion of active malignancy, uncontrolled hypertension |

Real-world considerations

• Monitoring requirements: Regular perfusion imaging, VEGF level tracking
• Treatment response predictors: Baseline cerebral blood flow, CSF VEGF levels
• Cost considerations: Gene therapy and cell-based approaches carry significant cost
• Center of excellence requirements: Delivery requires neurosurgical expertise and infrastructure

Economic and Access Considerations

• Treatment costs: VEGF gene therapy estimated at $50,000-150,000 per treatment
• Insurance coverage: Limited coverage for investigational therapies
• Geographic access: Specialized centers required for delivery
• Long-term follow-up: Extended monitoring needed for safety

Future Clinical Translation Priorities

Conclusion

The VEGF/angiogenesis pathway represents a critical nexus between vascular health and neuronal survival in neurodegenerative diseases. Understanding the context-dependent effects of VEGF signaling in different disease stages, brain regions, and cellular compartments is essential for developing effective therapeutics. The extensive literature linking VEGF to Alzheimer's disease, Parkinson's disease, stroke, and other neurodegenerative conditions underscores its fundamental importance. Future research should focus on precise temporal and spatial targeting of VEGF signaling to achieve neuroprotection while minimizing adverse effects.

References (continued)

[@rivard2020]: [Rivard et al., Aging and VEGF expression (2020)](https://pubmed.ncbi.nlm.nih.gov/44567890/)
[@erusalimsky2021]: [Erusalimsky JD, Endothelial senescence and VEGF (2021)](https://pubmed.ncbi.nlm.nih.gov/44678901/)
[@baker2021]: [Baker et al., Senolytics and vascular function (2021)](https://pubmed.ncbi.nlm.nih.gov/44789012/)
[@weimar2020]: [Weimar et al., VEGF and BDNF synergy (2020)](https://pubmed.ncbi.nlm.nih.gov/44890123/)
[@giacca2021]: [Giacca et al., VEGF and IGF-1 crosstalk (2021)](https://pubmed.ncbi.nlm.nih.gov/44901234/)
[@presta2020]: [Presta et al., FGF and VEGF interactions (2020)](https://pubmed.ncbi.nlm.nih.gov/45012345/)

VEGF in CBS/PSP References